MX2015013021A - 5-bromo-indirrubinas. - Google Patents
5-bromo-indirrubinas.Info
- Publication number
- MX2015013021A MX2015013021A MX2015013021A MX2015013021A MX2015013021A MX 2015013021 A MX2015013021 A MX 2015013021A MX 2015013021 A MX2015013021 A MX 2015013021A MX 2015013021 A MX2015013021 A MX 2015013021A MX 2015013021 A MX2015013021 A MX 2015013021A
- Authority
- MX
- Mexico
- Prior art keywords
- indirubins
- bromo
- compositions
- disclosed
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783290P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/028730 WO2014153023A1 (en) | 2013-03-14 | 2014-03-14 | 5-bromo-indirubins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013021A true MX2015013021A (es) | 2016-07-14 |
Family
ID=51581389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013021A MX2015013021A (es) | 2013-03-14 | 2014-03-14 | 5-bromo-indirrubinas. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20160068517A1 (https=) |
| EP (1) | EP2970310B1 (https=) |
| JP (1) | JP6422936B2 (https=) |
| KR (1) | KR102275112B1 (https=) |
| CN (1) | CN105283456B (https=) |
| AU (1) | AU2014236370C1 (https=) |
| BR (1) | BR112015023383A2 (https=) |
| CA (1) | CA2902914A1 (https=) |
| EA (1) | EA035877B1 (https=) |
| IL (1) | IL240916A0 (https=) |
| MX (1) | MX2015013021A (https=) |
| WO (1) | WO2014153023A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902914A1 (en) * | 2013-03-14 | 2014-09-25 | City Of Hope | 5-bromo-indirubins |
| US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
| JP7073109B2 (ja) | 2015-07-02 | 2022-05-23 | シティ・オブ・ホープ | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
| CA3080900C (en) * | 2017-10-31 | 2022-10-25 | Pelemed Co., Ltd. | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer |
| KR102443617B1 (ko) * | 2019-12-06 | 2022-09-16 | 광주과학기술원 | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 |
| KR102744517B1 (ko) * | 2022-02-14 | 2024-12-19 | 주식회사 펠레메드 | 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| FR2801216A1 (fr) * | 1999-11-23 | 2001-05-25 | Centre Nat Rech Scient | Utilisation de derives d'indirubine pour la fabrication de medicaments |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| WO2005107466A1 (en) * | 2004-05-12 | 2005-11-17 | Bayer Cropscience Gmbh | Plant growth regulation |
| US20060078494A1 (en) * | 2004-09-24 | 2006-04-13 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| US8552053B2 (en) * | 2005-12-23 | 2013-10-08 | Centre National De La Recherche Scientifique | 7-substituted indirubin-3′oximes and their applications |
| EP2149553B1 (en) * | 2008-08-01 | 2011-10-19 | Centre National de la Recherche Scientifique | 3', 6-substituted indirubins and their biological applications |
| EP2518139A1 (en) * | 2011-04-27 | 2012-10-31 | Universitätsklinikum Jena | Use of indirubin derivatives for producing pluripotent stem cells |
| US9051306B2 (en) | 2011-07-15 | 2015-06-09 | Nihon University | Indirubin derivative having highly selective cytotoxicity for malignant tumors |
| US10435367B2 (en) * | 2013-03-14 | 2019-10-08 | City Of Hope | Indirubin derivatives, and uses thereof |
| CA2902914A1 (en) | 2013-03-14 | 2014-09-25 | City Of Hope | 5-bromo-indirubins |
| US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
-
2014
- 2014-03-14 CA CA2902914A patent/CA2902914A1/en not_active Abandoned
- 2014-03-14 EA EA201591709A patent/EA035877B1/ru not_active IP Right Cessation
- 2014-03-14 EP EP14770647.7A patent/EP2970310B1/en active Active
- 2014-03-14 CN CN201480021350.4A patent/CN105283456B/zh not_active Expired - Fee Related
- 2014-03-14 MX MX2015013021A patent/MX2015013021A/es unknown
- 2014-03-14 BR BR112015023383A patent/BR112015023383A2/pt not_active Application Discontinuation
- 2014-03-14 JP JP2016502881A patent/JP6422936B2/ja not_active Expired - Fee Related
- 2014-03-14 KR KR1020157027506A patent/KR102275112B1/ko not_active Expired - Fee Related
- 2014-03-14 AU AU2014236370A patent/AU2014236370C1/en not_active Ceased
- 2014-03-14 WO PCT/US2014/028730 patent/WO2014153023A1/en not_active Ceased
-
2015
- 2015-08-30 IL IL240916A patent/IL240916A0/en unknown
- 2015-09-10 US US14/850,579 patent/US20160068517A1/en not_active Abandoned
-
2018
- 2018-02-15 US US15/898,151 patent/US20180170915A1/en not_active Abandoned
-
2020
- 2020-02-13 US US16/790,611 patent/US11306072B2/en active Active
-
2022
- 2022-03-09 US US17/690,323 patent/US20220274964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2970310A1 (en) | 2016-01-20 |
| JP2016514160A (ja) | 2016-05-19 |
| EA035877B1 (ru) | 2020-08-25 |
| KR102275112B1 (ko) | 2021-07-08 |
| US11306072B2 (en) | 2022-04-19 |
| EP2970310A4 (en) | 2016-09-07 |
| US20180170915A1 (en) | 2018-06-21 |
| IL240916A0 (en) | 2015-10-29 |
| AU2014236370B2 (en) | 2018-07-19 |
| EA201591709A1 (ru) | 2016-03-31 |
| CN105283456A (zh) | 2016-01-27 |
| KR20160006669A (ko) | 2016-01-19 |
| HK1220197A1 (zh) | 2017-04-28 |
| US20220274964A1 (en) | 2022-09-01 |
| JP6422936B2 (ja) | 2018-11-14 |
| BR112015023383A2 (pt) | 2017-07-18 |
| AU2014236370C1 (en) | 2019-01-17 |
| EP2970310B1 (en) | 2020-11-11 |
| AU2014236370A1 (en) | 2015-09-17 |
| CA2902914A1 (en) | 2014-09-25 |
| US20160068517A1 (en) | 2016-03-10 |
| WO2014153023A1 (en) | 2014-09-25 |
| CN105283456B (zh) | 2018-12-18 |
| US20200283421A1 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022231657A1 (en) | Compositions and Methods for Treating Cancer | |
| IL304820A (en) | Preparations and methods for the treatment of cancer | |
| IL273090B (en) | Methods and preparations for the treatment of cancer | |
| EP3060207A4 (en) | Methods and compositions for treating cancer | |
| EP3166640A4 (en) | Combination therapy compositions and methods for treating cancers | |
| EP3227317A4 (en) | Methods and compositons for treating cancer | |
| SG10201801433XA (en) | Composition and vaccine for treating prostate cancer | |
| EP3041470A4 (en) | Methods and compositions for selective and targeted cancer therapy | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| EP3200815A4 (en) | Methods and compositions for treating cancer | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| EP3085380A4 (en) | Composition for treating prostate cancer | |
| MX2016009663A (es) | Derivados de icariina. | |
| IL246607A0 (en) | Improved cellular preparations and methods for cancer treatment | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| EP3052102A4 (en) | Compositions and methods for treating cancers | |
| EP3004395A4 (en) | Compositions and methods for treating cancer | |
| PL2968226T3 (pl) | Kompozycje oksprenololu do leczenia raka | |
| EP3154544A4 (en) | Compositions and methods for treating cancers | |
| MX2015013021A (es) | 5-bromo-indirrubinas. | |
| MX2015008486A (es) | Composiciones y metodos para tratar infecciones bacterianas. | |
| EP3169333A4 (en) | Methods and compositions for enhancing cancer therapy | |
| EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers | |
| EP2984185A4 (en) | Methods and compositions for treating cancer |